{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:40:28Z","timestamp":1790800828928,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in non-immunized patients receiving a very low dosage of ATG versus BSX as induction. Study outcomes were patient\/graft survival, cumulative probabilities of biopsy proven acute rejection (BPAR), infectious episode including CMV and post-transplant diabetes (PTD). Cox, logistic or linear statistical models were used depending on the studied outcome and models were weighted on propensity scores. 100 patients received ATG (mean total dose of 2.0\u00a0mg\/kg) and 83 received BSX. Maintenance therapy was comparable. Patient and graft survival did not differ between groups, nor did infectious complications. There was a trend for a higher occurrence of a first BPAR in the BSX group (HR at 1.92; 95%CI: [0.77; 4.78]; <jats:italic>p<\/jats:italic> = 0.15) with a significantly higher BPAR episodes (17% vs 7.3%, <jats:italic>p<\/jats:italic> = 0.01). PTD occurrence was significantly higher in the BSX group (HR at 2.44; 95%CI: [1.09; 5.46]; <jats:italic>p<\/jats:italic> = 0.03). Induction with a very low dose of ATG in non-immunized recipients was safe and associated with a lower rate of BPAR and PTD without increasing infectious complications.<\/jats:p>","DOI":"10.3389\/ti.2023.10816","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T04:12:13Z","timestamp":1675397533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients"],"prefix":"10.3389","volume":"36","author":[{"given":"Christophe","family":"Masset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Kerleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Walencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Kervella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cantarovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Houzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Giral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Garandeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Nantes DIVAT Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD003897","DOI":"10.1002\/14651858.CD003897.pub3","article-title":"Interleukin 2 Receptor Antagonists for Kidney Transplant Recipients","volume":"1","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients","volume":"20","author":"Noel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19671977","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","year":"2009","journal-title":"Am J Transpl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/01.tp.0000200305.48244.a6","article-title":"In Vivo visualization of the Effect of Polyclonal Antithymocyte Globulins on the Microcirculation after Ischemia\/reperfusion in a Primate Model","volume":"81","author":"Chappell","year":"2006","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"613622","DOI":"10.1097\/TP.0000000000002804","article-title":"Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk","volume":"104","author":"Masset","year":"2020","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation (Harmony): an Open-Label, Multicentre, Randomised Controlled Trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.trim.2013.03.001","article-title":"Pharmacokinetic and Pharmacodynamic Studies of Two Different Rabbit Antithymocyte Globulin Dosing Regimens: Results of a Randomized Trial","volume":"28","author":"B\u00fcchler","year":"2013","journal-title":"Transpl Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell\u2013 and Antibody Mediated Rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transpl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/sim.3854","article-title":"The Performance of Different Propensity-Score Methods for Estimating Differences in Proportions (Risk Differences or Absolute Risk Reductions) in Observational Studies","volume":"29","author":"Austin","year":"2010","journal-title":"Stat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central Role of the Propensity Score in Observational Studies for Causal Effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"B12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal Structural Models and Causal Inference in Epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan-Meier Estimator and Log-Rank Test with Inverse Probability of Treatment Weighting for Survival Data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The Robust Inference for the Cox Proportional Hazards Model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"B15","article-title":"A Language and Environment for Statistical Computing","author":"R Development Core Team, .","year":"2010"},{"key":"B16","article-title":"Seven Years\u2019 Experience with Antilymphoblast Globulin for Renal Transplantation from Cadaver Donors","author":"Najarian","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0240929","DOI":"10.1371\/journal.pone.0240929","article-title":"Induction Therapy in Kidney Transplant Recipients: Description of the Practices According to the Calendar Period from the French Multicentric DIVAT Cohort","volume":"15","author":"Boucquemont","year":"2020","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/TP.0b013e31816dd596","article-title":"Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant Recipients","volume":"85","author":"Gurk-Turner","year":"2008","journal-title":"Transplantation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12659\/aot.881865","article-title":"Single-dose Thymoglobulin Induction in Living-Donor Renal Transplantation","volume":"16","author":"Schenker","year":"2011","journal-title":"Ann Transpl"},{"key":"B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.trim.2012.02.003","article-title":"The Effect of Low and Ultra-low Dosages Thymoglobulin on Peripheral T, B and NK Cells in Kidney Transplant Recipients","volume":"26","author":"Kho","year":"2012","journal-title":"Transpl Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.transproceed.2020.02.139","article-title":"Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience","volume":"52","author":"Jalalonmuhali","year":"2020","journal-title":"Transplant Proc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.transproceed.2020.01.054","article-title":"Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial","volume":"53","author":"Martinez-Mier","year":"2021","journal-title":"Transplant Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.transproceed.2007.06.021","article-title":"Do Anti-CD25 Monoclonal Antibodies Potentiate Posttransplant Diabetes Mellitus?","volume":"39","author":"Bay\u00e9s","year":"2007","journal-title":"Transplant Proc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/nep.12209","article-title":"Is Basiliximab Induction, a Novel Risk Factor for New Onset Diabetes after Transplantation for Living Donor Renal Allograft Recipients?: NODAT with Basiliximab Induction","volume":"19","author":"Prasad","year":"2014","journal-title":"Nephrology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/ndt\/gfw368","article-title":"Anti-thymocyte Globulins in Kidney Transplantation: Focus on Current Indications and Long-Term Immunological Side Effects","author":"Bamoulid","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/ajt.16883","article-title":"The Negative Impact of T Cell\u2013Mediated Rejection on Renal Allograft Survival in the Modern Era","volume":"22","author":"Rampersad","year":"2022","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/ajt.16964","article-title":"T Cell\u2013Mediated Rejection in Kidney Transplant Recipients: The end(point) Is Also the Beginning","volume":"22","author":"Chandran","year":"2022","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-Specific Cell-Mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+\/R+ Kidney Transplants at Risk of Late-Onset CMV Infection Regardless the Type of Induction Therapy","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/tri.12249","article-title":"Risk Factors for Impaired CD 4 + T\u2010cell Reconstitution Following Rabbit Antithymocyte Globulin Treatment in Kidney Transplantation","volume":"27","author":"Longuet","year":"2014","journal-title":"Transpl Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.kint.2020.08.010","article-title":"Time-dependent Lymphocyte Count after Transplantation Is Associated with Higher Risk of Graft Failure and Death","volume":"99","author":"Dujardin","year":"2021","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"247253","DOI":"10.1111\/j.1399-0012.2004.00148.x","article-title":"Cost-minimization Study Comparing Simulect \u00ae vs. Thymoglobulin\u00ae in Renal Transplant Induction","volume":"18","author":"Lilliu","year":"2004","journal-title":"Clin Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12341241","DOI":"10.1097\/TP.0000000000001310","article-title":"Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States","volume":"101","author":"Gharibi","year":"2017","journal-title":"Transplantation"},{"key":"B33","unstructured":"Standard Induction with Basiliximab versus No-Induction in Low Immunological Risk Kidney Transplant Recipients - Prospective Randomized Double Blind Controlled Clinical Trial\n            AjlanA\n          2021"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2023.10816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T04:12:17Z","timestamp":1675397537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2023.10816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":33,"alternative-id":["10.3389\/ti.2023.10816"],"URL":"https:\/\/doi.org\/10.3389\/ti.2023.10816","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"10816"}}